Blab Business
Aethlon Medical Announces Fiscal 2026 Earnings, Holds Investor Call
Aethlon Medical, Inc. (NASDAQ: AEMD) announced its fiscal year‑end March 31, 2026 financial results and held an earnings call on June 10, 2026 at 4:30 PM EDT. The call was recorded and included a forward‑looking statement disclaimer.
The call was moderated by the operator and opened by James Frakes, the company’s CEO, CFO, chief accounting officer, secretary and director. Frakes confirmed that the company released its financial results at 4:15 p.m. ET earlier that day.
Frakes also noted that the company’s investor page hosts the earnings release and that the call would provide an overview of strategy and recent developments. He indicated that a brief discussion of financials would follow before the Q&A segment.
Dr. Steven Larosa, Aethlon’s chief medical officer, was scheduled to provide the medical and clinical perspective on the company’s therapeutic pipeline. Larosa’s role is to guide the company’s research and development efforts in oncology and infectious disease treatments.
The conference call participants included representatives from Zacks Investment Research, specifically Marla Marin, and from Maxim Group, including Anthony Vendetti and Jeremy Pearlman. These analysts are known for covering the medical device and biotechnology sectors.
Aethlon Medical is a medical therapeutic company that focuses on developing products to treat cancer and life‑threatening infectious diseases. The company’s strategy centers on advancing its pipeline through clinical trials and regulatory milestones.
During the call, Frakes emphasized the importance of the company’s financial discipline and its commitment to maintaining a cash position sufficient to support ongoing research and development activities. He highlighted the company’s focus on operational efficiency.
The forward‑looking statement disclaimer, which was read at the beginning of the call, reminded participants that any projections or expectations about future performance are subject to risks and uncertainties. The disclaimer referenced the Securities Act of 1933 and the Securities Exchange Act of 1934.
After the introductory remarks, the call moved to a brief discussion of the company’s financial results. Frakes noted that the results were released earlier in the day and that the company would provide a concise overview of key financial metrics.
The call concluded with a question‑and‑answer session, during which analysts from Zacks and Maxim Group asked about the company’s clinical progress, regulatory strategy, and financial outlook. Frakes and Larosa responded to the questions, providing additional context on the company’s roadmap.
The earnings call is part of Aethlon’s regular investor‑relations activities, which include quarterly releases, annual reports, and shareholder meetings. The company’s website hosts all filings and press releases for public access.
As of the time of the call, Aethlon Medical had not yet announced any new acquisitions or major corporate actions beyond the ongoing clinical development of its pipeline. The company’s next scheduled event is its upcoming annual meeting, which will be held virtually in the coming months.
The call was moderated by the operator and opened by James Frakes, the company’s CEO, CFO, chief accounting officer, secretary and director. Frakes confirmed that the company released its financial results at 4:15 p.m. ET earlier that day.
Frakes also noted that the company’s investor page hosts the earnings release and that the call would provide an overview of strategy and recent developments. He indicated that a brief discussion of financials would follow before the Q&A segment.
Dr. Steven Larosa, Aethlon’s chief medical officer, was scheduled to provide the medical and clinical perspective on the company’s therapeutic pipeline. Larosa’s role is to guide the company’s research and development efforts in oncology and infectious disease treatments.
The conference call participants included representatives from Zacks Investment Research, specifically Marla Marin, and from Maxim Group, including Anthony Vendetti and Jeremy Pearlman. These analysts are known for covering the medical device and biotechnology sectors.
Aethlon Medical is a medical therapeutic company that focuses on developing products to treat cancer and life‑threatening infectious diseases. The company’s strategy centers on advancing its pipeline through clinical trials and regulatory milestones.
During the call, Frakes emphasized the importance of the company’s financial discipline and its commitment to maintaining a cash position sufficient to support ongoing research and development activities. He highlighted the company’s focus on operational efficiency.
The forward‑looking statement disclaimer, which was read at the beginning of the call, reminded participants that any projections or expectations about future performance are subject to risks and uncertainties. The disclaimer referenced the Securities Act of 1933 and the Securities Exchange Act of 1934.
After the introductory remarks, the call moved to a brief discussion of the company’s financial results. Frakes noted that the results were released earlier in the day and that the company would provide a concise overview of key financial metrics.
The call concluded with a question‑and‑answer session, during which analysts from Zacks and Maxim Group asked about the company’s clinical progress, regulatory strategy, and financial outlook. Frakes and Larosa responded to the questions, providing additional context on the company’s roadmap.
The earnings call is part of Aethlon’s regular investor‑relations activities, which include quarterly releases, annual reports, and shareholder meetings. The company’s website hosts all filings and press releases for public access.
As of the time of the call, Aethlon Medical had not yet announced any new acquisitions or major corporate actions beyond the ongoing clinical development of its pipeline. The company’s next scheduled event is its upcoming annual meeting, which will be held virtually in the coming months.
